Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
The Prostate · 2024
DOI: 10.1002/pros.24769 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Tokiyoshi Tanegashima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Phenylthiohydantoin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) are widely used due to their affordability and minimal severe side effects. However, their influence on the efficacy of cancer treatments, particularly androgen receptor signaling inhibitors (ARSIs), remains unclear. This study investigates the impact of PPI usage on the treatment outcomes in patients with metastatic castration‐resistant prostate cancer (mCRPC).
Methods
A total of 117 mCRPC patients were retrospectively analyzed and divided into two groups based on the concomitant use of PPI at the initiation of ARSI treatment: PPI+ ( n = 38) and PPI− ( n = 79). Patient characteristics, including age at ARSI treatment administered, prostate‐specific antigen (PSA) value at ARSI treatment administered, International Society of Urological Pathology grade group at prostate biopsy, metastatic site at ARSI treatment administered, prior docetaxel (DTX) treatment, and type of ARSI (abiraterone acetate or enzalutamide) were recorded. Progression‐free survival (PFS), overall survival (OS), and PSA response rates were compared between the two groups. Patients were further stratified by clinical background to compare PFS and OS between the two groups.
Results
The PPI− group exhibited significantly extended PFS and a trend toward improved OS. For PSA response (reduction of 50% or more from baseline), the rates were 62.3% and 45.9% in the PPI− group and the PPI+ group, respectively. For deep PSA response (reductions of 90% or more from baseline), the rates were 36.4% and 24.3% in the PPI− group and the PPI+ group, respectively. The effects were consistent across subgroups divided by prior DTX treatment and type of ARSI administered.
Conclusions
The administration of PPIs appears to diminish the therapeutic efficacy of ARSIs in mCRPC patients. Further prospective studies are needed to confirm these findings and explore the biological mechanisms involved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Tokiyoshi Tanegashima, Masaki Shiota
Zitieren
APA
Tanegashima, T., Shiota, M., Tsukahara, S., Mutaguch, J., Goto, S., Kobayashi, S., Matsumoto, T., & Eto, M. (2024). Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients. The Prostate. https://doi.org/10.1002/pros.24769
Vancouver
Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, et al. Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients. The Prostate. 2024. doi:10.1002/pros.24769
BibTeX
@article{Tanegashima2024,
author = {Tanegashima, Tokiyoshi and Shiota, Masaki and Tsukahara, Shigehiro and Mutaguch, Jun and Goto, Shunsuke and Kobayashi, Satoshi and Matsumoto, Takashi and Eto, Masatoshi},
title = {Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24769}
}
EUVIMED